Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria

Clinical Drug Investigation

Volumn 24, Issue 6, 2004, Pages 305-321

  Guest, Julian F ^a   Abegunde, Dele ^a   Ruiz, Francis J ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ADULT; ARTICLE; AUSTRIA; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERACTIVE BLADDER; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; URGE INCONTINENCE;

EID: 3042744096     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424060-00001     Document Type: Article

References (58)

1. International Continence Society Committee on Standardisation of Terminology. The standardisation of terminology of lower urinary tract function. Br J Obstet Gynaecol 1990; 97 Suppl. 6: 1-16
2. Abrams P, Wein AJ. The overactive bladder and incontinence: definitions and a plea for discussion. Neurourol Urodyn 1999; 18: 413-6
3. Chustecka Z. Urinary incontinence to be reclassified as a disease. Scrip 1998; 2351: 22
4. Urinary incontinence: new therapeutic options. PJB Publications Ltd, Richmond, Surrey, UK 2000
5. Temml C, Haidinger G, Schmidbauer J, et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000; 19: 259-71
6. Nasr SZ, Ouslander JG. Urinary incontinence in the elderly: causes and treatment options. Drugs Aging 1998; 12: 349-60
7. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women. JAMA 1998; 280 (23): 1995-2000
8. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
9. Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81 (6): 801-10
10. Ruscin JM, Morgenstern NE. Tolterodine use for symptoms for overactive bladder. Ann Pharmacother 1999; 33 (10): 1073-82
11. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs 1998; 55 (6): 813-20
12. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 Suppl. 6A: 90-6
13. Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141-7
14. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161 (6): 1809-12
15. Versi E, Appell RA, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95 (5): 718-21
16. Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther 1999; 21 (4): 634-42
17. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clinic Proc 2001; 76: 358-63
18. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose effect relationships. Clin Pharmacol Ther 1999; 65 (6): 672-84
19. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10mg once daily) with conventional oxybutynin tablets (5mg twice daily) in patients whose symptoms were stabilized on 5mg twice daily of oxybutynin. BJU Int 2000; 85 (7): 793-8
20. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54 (3): 420-3
21. Serrano Brambila EA, Quiroga Avila RG, Lorenzo Monterrubio JL, et al. Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women. Ginecol Obstet Mex 2000; 68: 174-81
22. Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999; 84: 646-51
23. Bemelmans BLH, Kiemeney LALM, Debruyne FMJ. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000; 37 (6): 709-13
24. Wang AC. Bladder-sphincter biofeedback as treatment of detrusor instability in women who failed to respond to oxybutynin. Changgeng Yi Xue Za Zhi 2000; 23: 590-9
25. Appell R, Diokno A, Antoci J, et al. One-year, prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population. Neurourol Urodyn 2000; 19 (4): 528
26. Lawrence M, Guay DR, Benson SR, et al. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20 (4): 470-5
27. Echols K, Verma U, Policaro F, et al. Idiopathic bladder hyperactivity and Ditropan: an efficacy and compliance issue. Obstet Gynecol 2000; 95: S24
28. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000; 16 (2): 149-55
29. Hofner K, Oelke M, Machtens S, et al. Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001; 19: 36-43
30. Dainer MJ, Zorn BH. Burch-Cooper's ligament sling procedure: an augmented incontinence operation. Tech Urol 2000; 6 (3): 175-7
31. Van Balken MR, Vandoninck V, Gisolf KW, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol 2001; 166 (3): 914-8
32. Govier FE, Litwiller S, Nitti V, et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol 2001; 165 (4): 1193-8
33. Social Security Schedule Costs. Nomenclature Generale des Actes Professionels et Nomenclature Generale des Actes Biologie Medicale. UCANSS. 2001
34. Dictionnaire Vidal, Paris 2001
35. Equête Anuelle du CREDES 2000
36. Annual abstract of statistics. Office for National Statistics, 2000
37. National Salaries. Income Institute National de la Statistique et des Etudes Economiques. Paris 2001
38. Hauptverband der Oesterreichischen Gebietskrankenkassen. Tarif fuer allgemeine Vertragsfachaertze der Wiener Gebietskrankenkasse, 2002. Wien: Hauptverband der Oeterreichischen Gebietskrankenkassen; 2002
39. Netten A, Curtis L. Unit costs of health and social care. University of Kent, Canterbury. Personal Social Services Research Unit. 2000
40. Monthly Index of Medical Specialites 2001 editions. London, Haymarket Publications Ltd
41. The New NHS 1999 Reference Costs. London: Department of Health, 2000
42. Hauptverband der Oesterreichischen Sozialversicherungstraeger. Heimittelverzeichnis 2002. Wien: Hauptverband der Oesterreichischen Sozialversicherungstraeger; 2002
43. NHS Charges [online]. Available from URL: http:// www.doh.gov.uk/ nhscharges/hc12.htm London: Department of Health, 2001
44. Bstaendig GmbH. Retail price list of incontinence pads. Vienna 2002
45. DRG Schedule Costs. French Ministry of Health, Paris 2001
46. Drummond MF, O'Brien BJ, Stoddart GL, et al. Cost benefit analysis. In: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford 1998: 205-31
47. Melchior H, Kumar V, Muller N, et al. National public health policies for prevention and care in urinary incontinence in the elderly. World J Urol 1998; 16 Suppl. 1: S71-3
48. Roy S. The cost of incontinence. Elder care 1997/98; 9 Suppl 6: 3-4
49. Wagner TH, Hu T-W. Economic costs of urinary incontinence in 1995. Urology 1998; 51: 355-61
50. Kelleher CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol 1995; 7: 404-8
51. Kobelt G, Jonsson L, Mattiasson A. Cost effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998; 17 (6): 599-611
52. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001; 7: S62-75
53. Plumb JM, Guest JF. Annual cost of erectile dysfunction to UK society. Pharmacoeconomics 1999; 16 (6): 699-709
54. Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost of illness model for the first five years following diagnosis. Pharmacoeconomics 1999; 15 (6): 597-610
55. Varney S, Guest JF. The annual societal cost of alcohol misuse in Scotland. Pharmacoeconomics 2002; 20 (13): 891-907
56. Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the Sickness Impact Profile. J Am Geriatri Soc 1991; 39: 378-82
57. Lenderking WR, Nackley JF, Anderson RB, et al. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics 1996; 9 (1): 11-23
58. Johannesson M, O'Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80: 557-62